XML 84 R64.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative and Licensing Arrangements - Recognized Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenues      
Total revenues $ 3,810,241 $ 2,458,779 $ 1,415,921
Collaboration revenue      
Revenues      
Total revenues 30,695 268,927 161,309
Collaboration revenue | Novartis      
Revenues      
Total revenues 30,695 268,927 161,309
Collaboration revenue | Tislelizumab      
Revenues      
Total revenues 2,113 77,345 49,148
Collaboration revenue | Ociperlimab      
Revenues      
Total revenues 18,259 192,469 112,161
Research and development service revenue | Novartis      
Revenues      
Total revenues 0 79,431 46,822
Research and development service revenue | Tislelizumab      
Revenues      
Total revenues 0 72,278 39,655
Research and development service revenue | Ociperlimab      
Revenues      
Total revenues 0 7,153 7,167
Right to access intellectual property revenue | Novartis      
Revenues      
Total revenues 0 104,477 104,994
Right to access intellectual property revenue | Ociperlimab      
Revenues      
Total revenues 0 104,477 104,994
Material rights revenue | Novartis      
Revenues      
Total revenues 0 71,980 0
Material rights revenue | Ociperlimab      
Revenues      
Total revenues 0 71,980 0
Other | Novartis      
Revenues      
Total revenues 30,695 13,039 9,493
Other | Tislelizumab      
Revenues      
Total revenues 2,113 5,067 9,493
Other | Ociperlimab      
Revenues      
Total revenues $ 18,259 $ 8,859 $ 0